In early 2024, we laid the foundation for what is now one of Europe’s most innovative pharmaceutical research companies. The founding of Pharmatech AI was not a spontaneous venture but the result of months of strategic planning. Our team of seasoned scientists, AI experts, and pharmaceutical specialists shared a common vision: to revolutionize drug discovery through artificial intelligence and cannabis-derived molecules.
The decisive step was securing our 60-hectare research facility in Mecklenburg-Vorpommern. This site not only provided ample space for our ambitious expansion plans but also the perfect conditions for our sustainability concept. The installation of a 55 MWp photovoltaic system now allows us to operate in a nearly energy-self-sufficient research environment, generating approximately 55 GWh of clean energy annually.
Key Challenges in This Phase:
- Building an interdisciplinary core team with top talent from AI and pharmaceutical research
- Developing a viable business model for commercializing AI-MDIP
- Designing lab infrastructure for cannabis research and nanomedicine
- Ensuring regulatory compliance from day one
“Back then, we faced a choice: become just another AI startup or create something truly groundbreaking,” recalls CEO Ercan Hayvali. “Our decision to establish a dedicated research facility with integrated cannabis production made all the difference.”